[1] |
International Warfarin Plarmacogenetics Consortium,KLEIN T E,ALTMAN R B,et al. Estimation of the warfarin dose with clinical and pharmacogenetic data[J]. N Engl J Med,2009,360(8):753-764.
|
[2] |
JIA L,WANG Z,MEN J,et al.Polymorphisms of VKORC1 and CYP2C9 are associated with warfarin sensitivity in Chinese population[J]. Ther Clin Risk Manag,2017,13:421-425.
|
[3] |
TOPKARA V K,KNOTTS R J,JENNINGS D L,et al.Effect of CYP2C9 and VKORC1 gene variants on warfarin response in patients with continuous-flow left ventricular assist devices[J]. ASAIO J,2016,62(5):558-564.
|
[4] |
WANG T L,LI H L,TJONG W Y,et al.Genetic factors contribute to patient-specific warfarin dose for Han Chinese[J]. Clin Chim Acta,2008,396(1-2):76-79.
|
[5] |
牛国平,魏园园. CYP2C9和VKORC1基因多态性与华法林剂量关系的研究[J]. 检验医学,2014,29(6):635-639.
|
[6] |
HUANG T S,ZHANG L,HE Q,et al.DNA sensors to assess the effect of VKORC1 and CYP2C9 gene polymorphisms on warfarin dose requirement in Chinese patients with atrial fibrillation[J]. Australas Phys Eng Sci Med,2017,40(1):249-258.
|
[7] |
STACK G,MAURICE C B.Warfarin pharmacogenetics reevaluated:subgroup analysis reveals a likely underestimation of the maximum pharmacogenetic benefit by clinical trials[J]. Am J Clin Pathol,2016,145(5):671-686.
|
[8] |
GALLEGO P,ROLDÁN V,MARIN F,et al. SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation[J]. Am J Med,2014,127(11):1083-1088.
|
[9] |
GRZYMALA-LUBANSKI B,LABAF A,ENGLUND E,et al.Mechanical heart valve prosthesis and warfarin- treatment quality and prognosis[J]. Thromb Res,2014,133(5):795-798.
|
[10] |
HYLEK E M.Vitamin K antagonists and time in the therapeutic range: implications, challenges, and strategies for improvement[J]. J Thromb Thrombolysis,2013,35(3):333-335.
|
[11] |
HORNE B D,LENZINI P A,WADELIUS M,et al.Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy[J]. Thromb Haemost,2012,107(2):232-240.
|
[12] |
JORGENSEN A L,FITZGERALD R J,OYEE J,et al.Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis[J]. PLoS One,2012,7(8):e44064.
|
[13] |
YANG J,CHEN Y,LI X,et al.Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: a systematic review and meta-analysis[J]. Int J Cardiol,2013,168(4):4234-4243.
|
[14] |
EPSTEIN R S,MOYER T P,AUBERT R E,et al.Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study)[J]. J Am Coll Cardiol,2010,55(25):2804-2812.
|
[15] |
娄莹,华潞,韩璐璐,等. 中国汉族人群华法林稳定剂量预测模型的建立与验证[J]. 中华心血管病杂志,2014,42(5):384-388.
|
[16] |
ZHANG L,ZHENG X,LONG Y,et al.D-dimer to guide the intensity of anticoagulation in Chinese patients after mechanical heart valve replacement: a randomized controlled trial[J]. J Thromb Haemost,2017,15(10):1934-1941.
|